Scarica l'app Stockscreener
1.41
12.96%
-0.21
Pre-mercato:
1.44
0.03
+2.13%
Precedente Chiudi:
$1.62
Aprire:
$1.6
Volume 24 ore:
1.21M
Relative Volume:
0.80
Capitalizzazione di mercato:
$79.63M
Reddito:
-
Utile/perdita netta:
$-30.05M
Rapporto P/E:
-2.2349
EPS:
-0.6309
Flusso di cassa netto:
$-27.71M
1 W Prestazione:
-27.69%
1M Prestazione:
-7.24%
6M Prestazione:
-45.98%
1 anno Prestazione:
-59.48%
Intervallo 1D:
$1.34
$1.60
Intervallo di 1 settimana:
$1.34
$1.99
Portata 52W:
$0.41
$4.44
Tuhura Biosciences Inc Stock (HURA) Company Profile
Nome
Tuhura Biosciences Inc
Settore
Industria
Telefono
813-875-6600
Indirizzo
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
1.41 | 79.63M | 0 | -30.05M | -27.71M | -0.6309 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-19 | Iniziato | Rodman & Renshaw | Buy |
| 2024-11-05 | Iniziato | Maxim Group | Buy |
Tuhura Biosciences Inc Borsa (HURA) Ultime notizie
EPS Watch: Does TuHURA Biosciences Inc stock reflect fundamentals2026 Technical Patterns & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
HURA SEC FilingsTuHURA Biosciences 10-K, 10-Q, 8-K Forms - stocktitan.net
TuHURA Biosciences, Inc. (NASDAQ:HURA): Is Breakeven Near? - Sahm
TuHURA Biosciences, Inc. (HURA) stock price, news, quote and history - Yahoo Finance UK
TuHURA Biosciences, Inc.'s (NASDAQ:HURA) Shift From Loss To Profit - Yahoo Finance
TuHURA Biosciences Reports 2025 Financial Results, Advances Phase 3 Cancer Trials and Expands Pipeline with VISTA Antibody Acquisition - Minichart
Tuhura Biosciences reports fourth quarter and full year 2025 financial results and provides a corporate update - marketscreener.com
Tuhura Biosciences Reports Fourth Quarter And Full Year 2025 Financial Results And Provides A Corporate Update - TradingView
TuHURA (Nasdaq: HURA) ramps R&D as IFx-2.0 enters Phase 3 - stocktitan.net
TuHURA says Merkel cell cancer Phase 3 enrollment ends mid-2027 - stocktitan.net
TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
TuHURA Biosciences (NASDAQ: HURA) maps Phase 3 trial and AML plans - Stock Titan
TuHURA R&D Jumps 75% in Q2 - AOL.com
Volatility Watch: Is TuHURA Biosciences Inc exposed to political riskDollar Strength & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
TuHURA Biosciences, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
TuHURA Biosciences (NASDAQ:HURA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
TuHURA Biosciences Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Layoff Watch: Does TuHURA Biosciences Inc. align with a passive investing strategyEarnings Trend Report & Low Risk High Win Rate Picks - baoquankhu1.vn
TuHURA Biosciences, Inc. Common Stock (HURA) Stock Price Today & Analysis - Gotrade
TuHURA Biosciences appoints Craig Tendler as chief medical officer By Investing.com - Investing.com Australia
TuHURA Biosciences, Inc.Common Stock (NQ: HURA - The Chronicle-Journal
TuHURA Biosciences appoints Craig Tendler as chief medical officer - Investing.com
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers - ChartMill
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Growth Report: How is TuHURA Biosciences Inc managing supply chain issuesWeekly Earnings Recap & Consistent Growth Equity Picks - baoquankhu1.vn
HURA Earnings History & Surprises | EPS & Revenue Results | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday - MarketBeat
Bull Bear: Is TuHURA Biosciences Inc a strong candidate for buy and hold2026 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Moving Averages: Is TuHURA Biosciences Inc attractive for institutional investorsPortfolio Growth Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Wall Street Zen Upgrades TuHURA Biosciences (NASDAQ:HURA) to "Hold" - MarketBeat
TuHURA Biosciences (NASDAQ:HURA) Trading Down 3.1%Here's Why - MarketBeat
Market Rankings: What dividend growth rate does TuHURA Biosciences Inc offerTrade Entry Report & Community Trade Idea Sharing Platform - baoquankhu1.vn
HURA Should I Buy - Intellectia AI
Aug PostEarnings: Will TuHURA Biosciences Inc outperform its industry peersPortfolio Gains Report & Capital Efficiency Focused Ideas - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
HURA Technical Analysis & ETF Price Forecast - Intellectia AI
TuHURA Biosciences stock gains after Nasdaq compliance - Investing.com India
Update Recap: How is TuHURA Biosciences Inc managing supply chain issuesJuly 2025 Highlights & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
TuHURA Biosciences stock gains after Nasdaq compliance By Investing.com - Investing.com South Africa
TuHURA Biosciences regains Nasdaq listing compliance - Investing.com
Cancer immunotherapy firm TuHURA keeps share price over $1 to satisfy Nasdaq - Stock Titan
Critical Review: Fate Therapeutics (NASDAQ:FATE) vs. TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences - Nasdaq
HURA.O Technical Analysis & Stock Price Forecast - Intellectia AI
Cancer immunotherapy developer TuHURA plans back-to-back investor events in March - stocktitan.net
TuHURA Biosciences (HURA) to Release Earnings on Wednesday - MarketBeat
TuHura files IND for leukemia drug combination study By Investing.com - Investing.com India
TuHura files IND for leukemia drug combination study - Investing.com Australia
Tuhura Files Investigational New Drug Application for Tbs-2025 in the Treatment of Blood-Related Cancers - marketscreener.com
New TuHURA antibody aims to boost leukemia drug response - Stock Titan
Is TuHURA Biosciences Inc. a strong growth stockJuly 2025 Technicals & Technical Entry and Exit Tips - mfd.ru
Tuhura Biosciences Inc Azioni (HURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):